Maxim Group Initiates Coverage On Anebulo Pharmaceuticals with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Michael Okunewitch has initiated coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy rating and a price target of $6.
September 21, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anebulo Pharmaceuticals has been initiated with a Buy rating by Maxim Group, with a price target of $6.
The initiation of coverage by Maxim Group with a Buy rating is a positive signal for Anebulo Pharmaceuticals. The price target of $6 indicates the analyst's confidence in the company's potential growth. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100